| Overview |
| bs-9209R |
| SERPINA10 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ZPI/SERPINA10 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 51156 |
| Protein Z dependent protease inhibitor; Protein Z dependent protease inhibitor precursor; Protein Z-dependent protease inhibitor; PZ dependent protease inhibitor; PZ-dependent protease inhibitor; PZI; serine or cysteine proteinase inhibitor clade A alpha 1 antiproteinase antitrypsin member 10 ; Serpin A10; Serpin peptidase inhibitor clade A alpha 1 antiproteinase antitrypsin member 10; SERPINA 10; SERPINA10; ZPI; ZPI_HUMAN. |
| ZPI, also known as SERPINA10 (serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10) or PZI, is a 444 amino acid secreted protein that functions as a Protein Z-dependent protease inhibitor. Expressed by the liver, ZPI is secreted into the plasma where, in the presence of calcium, Protein Z and phospholipids, it inhibits the activated pro-coagulation factors X and XI (Factor X and Factor XI). This inhibition helps properly regulate intravenous blood clotting. ZPI, a member of the serpin protein family, contains five potential N-linked glycosylation sites and a tyrosine at position 387 which, when disrupted, renders ZPI inactive. Defects in the gene encoding ZPI may increase susceptibility to venous thrombosis, the formation of blood clots within a vein. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
IHC-P1:200-400 |
| IHC-P |
IFIHC-P1:50-200 |
| IHC-F |
|
| IF |
|